strains led to the identification of compounds 5 and 6 as hits active at submicromolar concentrations. Derivatives of these compounds were synthesized as a preliminary structure–activity-relationship study. Among them, 7 and 11 were highly active against poliovirus Sabin 1–3. Compound 11 was also very potent against a large panel of wild and vaccine-derived polioviruses. Time-of-addition experiments suggest
根除脊髓灰质炎的最后阶段比早期阶段更加困难,开发有效的药物和治疗方法被认为是当务之急;因此,这项研究正在进行中。我们针对脊髓灰质炎病毒 Sabin 菌株的内部
化学库进行筛选,结果鉴定出化合物5和6在亚微摩尔浓度下具有活性。合成这些化合物的衍
生物作为初步的结构-活性-关系研究。其中,7和11对脊髓灰质炎病毒Sabin 1-3具有高度活性。化合物11对大量野生和疫苗衍生的脊髓灰质炎病毒也非常有效。添加时间实验表明,5和7可能在病毒复制的早期阶段具有活性,而11在病毒复制的所有阶段以相同浓度具有活性。应用基于
配体的方法来寻找新化合物和已知的脊髓灰质炎病毒
抑制剂共有的结构特征。